目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基...目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基础上辅助应用维生素B6联合鼠神经生长因子治疗。比较两组患儿临床疗效,治疗前后外周血miR-99a-5p、miR-125b-5p、泛素羧基末端水解酶L1(ubiquitin C-terminal hydrolase-L1,UCH-L1)水平变化和对脑电活动的影响,评估患儿智力水平和生活质量改善情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组miR-99a-5p、miR-125b-5p、UCH-L1和θ波水平,均明显低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组语言智商、操作智商和总智商评分,儿童癫痫生活质量量表(quality of life in childhood epilepsy,QOLCE)总分,均明显高于对照组,差异有统计学意义(P<0.05)。结论维生素B6联合鼠神经生长因子治疗难治性癫痫效果较佳,可显著降低患儿外周血miR-99a-5p、miR-125b-5p、UCH-L1水平,控制脑电活动,从而改善患儿智力水平和生活质量。展开更多
目的探析斑蝥酸钠维生素B6注射液辅助化疗治疗肺腺癌的效果。方法在2019年8月至2022年8月北京市昌平区医院收治的肺腺癌患者中选取74例配合研究,依据随机数字表法分为两组,每组37例。对照组采用贝伐珠单抗+培美曲塞二钠+卡铂治疗,观察...目的探析斑蝥酸钠维生素B6注射液辅助化疗治疗肺腺癌的效果。方法在2019年8月至2022年8月北京市昌平区医院收治的肺腺癌患者中选取74例配合研究,依据随机数字表法分为两组,每组37例。对照组采用贝伐珠单抗+培美曲塞二钠+卡铂治疗,观察组采用斑蝥酸钠维生素B6注射液辅助化疗治疗。比较两组生活质量评分、各症状评分及不良反应发生率。结果两组治疗前各症状评分比较差异无统计学意义(P>0.05),观察组治疗后各症状评分低于对照组(P<0.05),治疗前两组肺功能指标比较差异无统计学意义(P>0.05),治疗后观察组第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))(1.98±0.42)、用力肺活量(forced vital capacity,FVC)(3.39±0.12)、FEV_(1)/FVC(76.12±8.32)较对照组高,组间差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。观察组治疗后生活质量评分较对照组高(P<0.05)。结论肺腺癌患者采用斑蝥酸钠维生素B6注射液辅助化疗治疗效果明显,其机体肿瘤标志物指标水平明显下降,患者各症状得到改善,有效预防不良反应发生。展开更多
Cytochromes P450(CYPs)play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75%of the total metabolism of commercially available drugs,including chemotherapeutics.The gene expr...Cytochromes P450(CYPs)play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75%of the total metabolism of commercially available drugs,including chemotherapeutics.The gene expression and enzyme activity of CYPs are variable between individuals,which subsequently leads to different patterns of susceptibility to carcinogenesis by genotoxic xenobiotics,as well as differences in the efficacy and toxicity of clinically used drugs.This research aimed to examine the presence of the CYP2B6*9 polymorphism and its possible association with the incidence of B-CLL in Egyptian patients,as well as the clinical outcome after receiving cyclophosphamide chemotherapy.DNA was isolated from whole blood samples of 100 de novo B-CLL cases and also from 100 sex-and age-matched healthy individuals.The presence of the CYP2B6*9(G516T)polymorphism was examined by PCR-based allele specific amplification(ASA).Patients were further indicated for receiving chemotherapy,and then they were followed up.The CYP2B6*9 variant indicated a statistically significant higher risk of B-CLL under different genetic models,comprising allelic(T-allele vs.G-allele,OR=4.8,p<0.001)and dominant(GT+TT vs.GG,OR=5.4,p<0.001)models.Following cyclophosphamide chemotherapy,we found that the patients with variant genotypes(GT+TT)were less likely to achieve remission compared to those with the wild-type genotype(GG),with a response percentage of(37.5%vs.83%,respectively).In conclusion,our findings showed that the CYP2B6*9(G516T)polymorphism is associated with B-CLL susceptibility among Egyptian patients.This variant greatly affected the clinical outcome and can serve as a good therapeutic marker in predicting response to cyclophosphamide treatment.展开更多
文摘目的探讨维生素B6联合鼠神经生长因子治疗难治性癫痫(refractory epilepsy,RE)患儿的疗效。方法选取RE患儿89例,根据住院号随机分为观察组(n=43)和对照组(n=46)。对照组在原抗癫痫药物治疗基础上联合应用左乙拉西坦片,观察组在对照组基础上辅助应用维生素B6联合鼠神经生长因子治疗。比较两组患儿临床疗效,治疗前后外周血miR-99a-5p、miR-125b-5p、泛素羧基末端水解酶L1(ubiquitin C-terminal hydrolase-L1,UCH-L1)水平变化和对脑电活动的影响,评估患儿智力水平和生活质量改善情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组miR-99a-5p、miR-125b-5p、UCH-L1和θ波水平,均明显低于对照组,差异有统计学意义(P<0.05)。治疗后,观察组语言智商、操作智商和总智商评分,儿童癫痫生活质量量表(quality of life in childhood epilepsy,QOLCE)总分,均明显高于对照组,差异有统计学意义(P<0.05)。结论维生素B6联合鼠神经生长因子治疗难治性癫痫效果较佳,可显著降低患儿外周血miR-99a-5p、miR-125b-5p、UCH-L1水平,控制脑电活动,从而改善患儿智力水平和生活质量。
文摘目的探析斑蝥酸钠维生素B6注射液辅助化疗治疗肺腺癌的效果。方法在2019年8月至2022年8月北京市昌平区医院收治的肺腺癌患者中选取74例配合研究,依据随机数字表法分为两组,每组37例。对照组采用贝伐珠单抗+培美曲塞二钠+卡铂治疗,观察组采用斑蝥酸钠维生素B6注射液辅助化疗治疗。比较两组生活质量评分、各症状评分及不良反应发生率。结果两组治疗前各症状评分比较差异无统计学意义(P>0.05),观察组治疗后各症状评分低于对照组(P<0.05),治疗前两组肺功能指标比较差异无统计学意义(P>0.05),治疗后观察组第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))(1.98±0.42)、用力肺活量(forced vital capacity,FVC)(3.39±0.12)、FEV_(1)/FVC(76.12±8.32)较对照组高,组间差异有统计学意义(P<0.05);观察组不良反应发生率低于对照组(P<0.05)。观察组治疗后生活质量评分较对照组高(P<0.05)。结论肺腺癌患者采用斑蝥酸钠维生素B6注射液辅助化疗治疗效果明显,其机体肿瘤标志物指标水平明显下降,患者各症状得到改善,有效预防不良反应发生。
文摘Cytochromes P450(CYPs)play a prominent role in catalyzing phase I xenobiotic biotransformation and account for about 75%of the total metabolism of commercially available drugs,including chemotherapeutics.The gene expression and enzyme activity of CYPs are variable between individuals,which subsequently leads to different patterns of susceptibility to carcinogenesis by genotoxic xenobiotics,as well as differences in the efficacy and toxicity of clinically used drugs.This research aimed to examine the presence of the CYP2B6*9 polymorphism and its possible association with the incidence of B-CLL in Egyptian patients,as well as the clinical outcome after receiving cyclophosphamide chemotherapy.DNA was isolated from whole blood samples of 100 de novo B-CLL cases and also from 100 sex-and age-matched healthy individuals.The presence of the CYP2B6*9(G516T)polymorphism was examined by PCR-based allele specific amplification(ASA).Patients were further indicated for receiving chemotherapy,and then they were followed up.The CYP2B6*9 variant indicated a statistically significant higher risk of B-CLL under different genetic models,comprising allelic(T-allele vs.G-allele,OR=4.8,p<0.001)and dominant(GT+TT vs.GG,OR=5.4,p<0.001)models.Following cyclophosphamide chemotherapy,we found that the patients with variant genotypes(GT+TT)were less likely to achieve remission compared to those with the wild-type genotype(GG),with a response percentage of(37.5%vs.83%,respectively).In conclusion,our findings showed that the CYP2B6*9(G516T)polymorphism is associated with B-CLL susceptibility among Egyptian patients.This variant greatly affected the clinical outcome and can serve as a good therapeutic marker in predicting response to cyclophosphamide treatment.
